In a study published in Nature Communications, researchers at the Beijing Institute of Stem Cells and Regeneration (BISCRM) ...

successfully utilizing Casgevy gene therapy through CRISPR gene editing technology to treat a 13-year-old patient with thalassemia major. The achievement is the first of its kind outside of clinical ...

The growing occurrence of genetic disorders like sickle cell anemia, cystic fibrosis, and muscular dystrophy is fueling the demand for gene therapy and genome editing solutions, as these approaches ...

India is known as the “Thalassemia capital of the world.” It has the highest number of patients with thalassemia major in the world. India has around 50 million (5 crore) carriers of the ß ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

CRISPR technology, driven by Cas9, redefines gene editing, facilitating targeted DNA modifications that advance genetic ...

The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...

A proof-of-concept study shows that CRISPR-Cas9 can eliminate extra chromosome copies in Down ... similar approaches could be applied to neurons and glial cells, offering a potential treatment for ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ: CRSP) stands against ...

Headquartered in Zug, Switzerland, CRISPR Therapeutics AG (NASDAQ:CRSP) develops transformative gene-based medicines for serious diseases through its proprietary CRISPR/Cas9 platform. The CRISPR ...

When was the Monster Hunter Wilds beta? The MHWilds OBT allowed players to experience a limited portion of the game ahead of launch, including a character creator to put together the perfect main ...

Especially for therapies, hurdles remain. One is cost. Casgevy, the CRISPR cure for sickle-cell disease and beta-thalassemia, is expensive to make and to buy. Health-care systems in America and ...